HC Wainwright Reaffirms Buy Rating for SABS

On June 15, 2026, HC Wainwright reiterated its buy rating for SABS, setting a price target of $10. Analyst Emily Bodnar expressed confidence in the company's prospects despite current market challenges. Shares of SABS were trading at $3.33 at the time of the rating.

Other Institutional Activity in SABS

Vivo Capital, LLC maintained its position in SABS, holding steady at 11.42 million shares valued at about $43.74 million. Caligan Partners LP established a new stake with 7.97 million shares worth approximately $30.51 million. Perceptive Advisors LLC significantly increased its holdings by 5.63 million shares, bringing its total to 6.43 million shares valued at $24.63 million. Meanwhile, RA Capital Management, L.P. and Commodore Capital LP held their positions steady, each with 4.40 million shares valued at $16.86 million.

SABS Stock Snapshot

SABS shares are currently trading at $3.33. The stock has been receiving attention from several analysts, with a recent reiterated buy rating from HC Wainwright. While the company's market cap and other financial metrics were not detailed, the stock's price target suggests potential upside from its current trading level.

Insider Buying and Selling at SAB Biotherapeutics, Inc.

Recent insider transactions at SABS include significant purchases on February 3, 2026. Chief Financial Officer Lucy To and Chief Operating Officer Christoph Lawrence Bausch each acquired 2.4 million shares, while Chief Medical Officer Alexandra Kropotova and CEO Samuel Reich bought 2.4 million and 4.8 million shares, respectively. These transactions were not part of any pre-planned trading program.

Analysts Set New Price Targets

On June 15, 2026, HC Wainwright reiterated its buy rating for SABS with a $10 price target. Earlier, on May 22, 2026, Citigroup initiated coverage with a buy rating and an $11 target. Jefferies also started coverage with a buy rating and an $11 target on May 20, 2026. The consensus among analysts is positive, with a mean target price reflecting optimism about SABS's future performance.

Bottom Line

HC Wainwright's reiterated buy rating for SABS highlights continued analyst confidence in the company's potential, as reflected in its $10 price target. This optimism is mirrored by recent institutional activity, with significant stake increases by several funds. Insider buying by key executives further underscores confidence in SABS's prospects. As always, it's important to remember that analyst ratings and insider transactions are just part of the broader picture investors should consider.